Biontech and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 in hard-to-treat nsclc at asco

Mainz, germany, and rockville, maryland, usa, june 2, 2023 (globe newswire) — biontech se (nasdaq: bntx, “biontech”) and oncoc4, inc. (“oncoc4”), today announced positive preliminary data from the ongoing phase 1/2 trial with the companies' anti-ctla-4 antibody candidate, bnt316/onc-392 (gotistobart), in a patient cohort with metastatic, pd-(l)1-resistant non-small cell lung cancer (“nsclc”). the preliminary results show encouraging clinical anti-tumor activity for bnt316/onc-392 as a monotherapy in a hard-to-treat patient population, as well as a manageable safety profile. the data will be presented in a poster discussion session at the 2023 american society of clinical oncology (asco) annual meeting by kai he, m.d., ph.d., pelotonia institute for immuno-oncology, the ohio state university comprehensive cancer center – arthur g. james cancer hospital and richard j. solove research institute, columbus, ohio, usa.
BNTX Ratings Summary
BNTX Quant Ranking